Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer

MT Newswires Live

06/03

Ideaya Biosciences (IDYA) said Wednesday it will collaborate with Roche to evaluate its investigational compound IDE892 combined with Roche's RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.

Ideaya said it will sponsor the clinical trial while Roche will supply RG6505, with both companies jointly overseeing the program.

The companies will retain commercial rights to their respective compounds, including as monotherapy and as combination therapies, according to Ideaya.

The company said it is currently evaluating IDE892 in a phase 1 dose escalation study in MTAP-deleted solid tumors.

Ideaya Biosciences shares were down 1.5% in premarket activity Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2640909176"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640909176\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640909176?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640909176","market":"nz","top_or_hot":-1,"title":"Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer","media":"MT Newswires Live","content":"<html><body><p> Ideaya Biosciences (IDYA) said Wednesday it will collaborate with Roche to evaluate its investigational compound IDE892 combined with Roche's RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.</p><p>Ideaya said it will sponsor the clinical trial while Roche will supply RG6505, with both companies jointly overseeing the program.</p><p>The companies will retain commercial rights to their respective compounds, including as monotherapy and as combination therapies, according to Ideaya.</p><p>The company said it is currently evaluating IDE892 in a phase 1 dose escalation study in MTAP-deleted solid tumors.</p><p>Ideaya Biosciences shares were down 1.5% in premarket activity Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIdeaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ideaya Biosciences (IDYA) said Wednesday it will collaborate with Roche to evaluate its investigational compound IDE892 combined with Roche's RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.</p><p>Ideaya said it will sponsor the clinical trial while Roche will supply RG6505, with both companies jointly overseeing the program.</p><p>The companies will retain commercial rights to their respective compounds, including as monotherapy and as combination therapies, according to Ideaya.</p><p>The company said it is currently evaluating IDE892 in a phase 1 dose escalation study in MTAP-deleted solid tumors.</p><p>Ideaya Biosciences shares were down 1.5% in premarket activity Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640909176","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640909176","pubTimestamp":1780486513,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ideaya Biosciences (IDYA) said Wednesday it will collaborate with Roche to evaluate its investigational compound IDE892 combined with Roche's RG6505 in patients with MTAP-deleted, RAS-mutant pancreati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences","BK4139":"生物科技"},"translate_title":"Ideaya Biosciences与罗氏合作测试胰腺癌联合疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"Ideaya Biosciences (IDYA) said Wednesday it will collaborate with Roche to evaluate its investigational compound IDE892 combined with Roche's RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.Ideaya said it will sponsor the clinical trial while Roche will supply RG6505, with both companies jointly overseeing the program.The companies will retain commercial rights to their respective compounds, including as monotherapy and as combination therapies, according to Ideaya.The company said it is currently evaluating IDE892 in a phase 1 dose escalation study in MTAP-deleted solid tumors.Ideaya Biosciences shares were down 1.5% in premarket activity Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}